Kopran Limited (NSE:KOPRAN)

India · Delayed Price · Currency is INR

267.00

+7.24 (2.79%)

Nov 11, 2026, 1:15 PM IST

Market Cap	12.88B +68.9%
Revenue (ttm)	7.94B +34.2%
Net Income	393.01M +123.3%
EPS	8.16 +124.6%
Shares Out	n/a
PE Ratio	32.73
Forward PE	n/a
Dividend	3.00 (1.12%)
Ex-Dividend Date	Aug 11, 2026

Volume	141,584
Open	258.56
Previous Close	259.76
Day's Range	258.56 - 267.01
52-Week Range	107.00 - 295.83
Beta	1.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Kopran

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, ur... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1958

Employees 1,156

Stock Exchange National Stock Exchange of India

Ticker Symbol KOPRAN

Full Company Profile

Financial Performance

In fiscal year 2026, Kopran's revenue was 6.81 billion, an increase of 8.23% compared to the previous year's 6.30 billion. Earnings were 257.31 million, a decrease of -33.26%.

Financial Statements